IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions

Bulletin of the NYU Hospital for Joint Diseases

Volumn 70, Issue 3, 2012, Pages 195-199

  Woodrick, Robert S ^a   Ruderman, Eric M ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; CHOLESTEROL; CLAZAKIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; INTERLEUKIN 8; LIPID; METHOTREXATE; SARILUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TARGETING; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LIPID BLOOD LEVEL; MONOTHERAPY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPONDYLOARTHROPATHY; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; SPONDYLARTHROPATHIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869425250     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008 Nov;67(11):1516-23
2. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to diseasemodifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008 Oct;58(10):2968-80
3. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010 Jan;69(1):88-96
4. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006 Sep;54(9):2817-29
5. Gabay C, et al. Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the Phase 4 ADACTA trial. Presented at the EULAR Congress LB0003, Berlin, 2012
6. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010 May;64(5):625-39
7. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010 Jun;69(6):964-975
8. Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther. 2006:8(3):R66
9. Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011 Apr:70(4):583-9
10. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2012 Jul 7. [Epub ahead of print]
11. Dougados M, et al. Clinical, radiographic, and immunogenic effects after 1 year of tocilizumab (TCZ)-based treatment strategy with and without methotrexate (MTX) in RA: the ACT-RAY study. EULAR Congress THU0093 (Berlin, 2012)
12. Bykerk VP, Ostör AJ, Alvaro-Gracia J, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, openlabel study close to clinical practice. Ann Rheum Dis. 2012 Jul 6. [Epub ahead of print]
13. Ogata, A. & Group, M.S. The MUSASHI study: Comparison of subcutaneous tocilizumab monotherapy versus intravenous tocilizumab monotherapy: Results from a double-blind, parallel-group, comparative phase III non-inferiority study in Japanese patients with rheumatoid arthritis. EULAR Congress FRI0180 (Berlin, 2012)
14. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the doubleblind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011 Mar:63(3):609-21
15. Finzel S, Rech J, Schmidt S, et al. Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study. Ann Rheum Dis. 2012 May 14. [Epub ahead of print]
16. Karsdal MA, Schett G, Emery P, et al. IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE Study (NCT00106522). Semin Arthritis Rheum. 2012 Mar 5. [Epub ahead of print]
17. Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford). 2007 Jul;46(7):1191-9
18. Yamanaka H, et al. The advantage of early intervention by tocilizumab-Full analysis of all-case postmarketing surveillance in 7,901 patients in Japan. Presented at the EULAR Congress THU0092, Berlin, 2012
19. Mori S, Ueki Y, Hirakata N, et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012 Sep 6. [Epub ahead of print]
20. Dragonas C, Ehrenstein B, Fleck M. Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection. Rheumatology (Oxford). 2010 Aug;51(8):1520-1
21. De Benedetti F, et al. Efficacy and safety of tocilizumab (TCZ) in patients (PTS) with systemic juvenile idiopathic arthritis (SJIA): TENDER 52-week data. Presented at the EULAR Congress OP0006, Berlin, 2011
22. De Benedetti F, et al. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from TENDER, a phase 3 clinical trial. Presented at the EULAR Congress FRI0328, Berlin, 2012
23. Inaba Y, Ozawa R, Aoki C, et al. Radiologic analysis of the effect of tocilizumab on hands and large joints in children with systemic juvenile idiopathic arthritis. Mod Rheumatol. 2012 Jul 13. [Epub ahead of print]
24. Shimizu M, Nakagishi Y, Kasai K, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritisassociated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012 May;58(2):287-94
25. Sieper J, Porter-Brown B, Thompson L, et al. Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): Results of a phase 2, international multicentre, randomised, double-blind, placebo-controlled trial. EULAR Congress OP0166 (Berlin, 2012)
26. Lekpa FK, Poulain C, Wendling D, et al. Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study. Arthritis Res Ther. 2012 Mar 9;14(2):R53
27. Sieper J, Inman RD, Badalamenti S, et al. Sarilumab for the treatment of ankylosing spondylitis:Results of a phase 2, randomized, double-blind, placebo-controlled, international study. Presented at the EULAR Congress OP0169, Berlin, 2012
28. Huizinga T, et al. Sarilumab for the treatment of moderateto-severe rheumatoid arthritis: Results of a phase 2, randomized, double-blind, placebo-controlled, international study. Presented at the EULAR Congress OP0023, Berlin, 2012
29. Mease P, Strand V, Shalamberidze L, et al. A phase II, doubleblind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis. 2012 Jul;71(7):1183-9.